McKesson Corporation Fiscal 2024 Financial Results Fiscal 2025 Outlook May 7, 2024 Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the ...

McKESSON CORPORATION REPORTS FISCAL 2024 FOURTH QUARTER AND FULL YEAR RESULTS Fourth Quarter Highlights: • Consolidated revenues of $76.4 billion increased by 11%. • Earnings per diluted share from continuing operations of $6.02 increased $0.31. • Adjusted Earnings per Diluted Share of $6.18 decreased by 14%. Full Year Highlights: • Consolidated revenues of $309.0 billion increased by 12%. • Earnings per diluted share from continuing operations of $22.39 decreased $2.66. • Adjusted Earnings per Diluted Shar ...

Wall Street analysts expect McKesson (MCK) to post quarterly earnings of $6.34 per share in its upcoming report, which indicates a year-over-year decline of 11.8%. Revenues are expected to be $78.72 billion, up 14.2% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Prior to a company's earn ...

The market expects McKesson (MCK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on May 7, 2024, might help the stock move higher if these key numbers are better t ...

股价表现 - McKesson (MCK) 最新收盘价为 $543.30，较前一个交易日上涨了 +0.62% [1] - McKesson 的股价在过去一个月上涨了 0.58%，超过了医疗行业的下跌幅度 [2] 财务预测 - McKesson 即将公布财报，预计每股收益为 $6.34，同比下降 11.82%，预计营收为 $78.72 亿美元，同比增长 14.23% [3] - Zacks Rank 模型显示 McKesson 目前的评级为 3 (Hold)，过去 30 天内，预期每股收益上调了 0.18% [6] 估值指标 - McKesson 目前的前瞻市盈率为 17.39，低于行业平均值 17.6 [7] - McKesson 目前的 PEG 比率为 1.43，略低于医疗 - 牙科用品行业的平均 PEG 比率 1.8 [8] 行业排名 - 医疗 - 牙科用品行业属于医疗行业，目前的 Zacks Industry Rank 为 71，在所有行业中排名前 29% [9] - Zacks Industry Rank 显示，评级较高的行业通常表现优于评级较低的行业 [10]

Zacks Premium - Zacks Premium提供了多种方式帮助投资者更加聪明和自信地投资[1] Zacks Style Scores - Zacks Style Scores是一组辅助指标，帮助投资者挑选未来30天内市场表现最佳的股票[3] - Style Scores分为价值评分、成长评分、动量评分和VGM评分，分别帮助价值投资者、成长投资者和动量投资者挑选股票[5][6][7][8] Zacks Rank - Zacks Rank是一种专有的股票评级模型，利用盈利预期修订来帮助投资者构建成功的投资组合[9] McKesson (MCK) - McKesson (MCK)是一家总部位于旧金山的医疗保健服务和信息技术公司，具有Zacks Rank 3和VGM Score B[15][16] - MCK具有动量Style Score B，股价在过去四周上涨了0.6%[17] - 在2024财年，两位分析师在过去60天内上调了其盈利预期，Zacks Consensus Estimate增加至27.59美元，平均盈利惊喜率为9.1%[18] - MCK具有稳固的Zacks Rank和顶级的动量和VGM Style Scores，值得投资者关注[19]

公司业绩 - McKessonCorporation (MCK) 通过战略合作和分销解决方案部门的实力，为增长做好准备[1] - 公司的盈利预计在未来五年将提高11.9%[3] - McKesson在过去四个季度中的盈利超出预期，平均超出9.11%[4] - McKesson的第三季度财报表现强劲，整体营收大幅增长[8] 投资者关注点 - 投资者对McKesson强劲的生物制剂业务感到乐观[5] - 分销解决方案部门继续面临较弱的通用药物价格趋势[9] 公司发展策略 - 公司继续积极追求交易、剥离和收购以推动增长[7] - 公司面临来自各种批发商、服务商、制造商和第三方物流公司的激烈竞争[11] 财务展望 - Zacks对2024财年营收的预期为310.28亿美元，调整后每股盈利预期为27.62美元[13]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. Wha ...

Zacks Rank和价值投资 - Zacks Rank强调盈利预期和预期修订，寻找强劲股票[1] - 价值投资是一种被广泛喜爱的趋势，寻找被市场低估的公司[2] - Zacks开发了Style Scores系统，突出显示具有特定特征的股票，价值投资者会对“价值”类别中得分高的股票感兴趣[3] McKesson (MCK)分析 - McKesson (MCK)目前具有Zacks Rank 2（买入）和价值评级A[4] - MCK的市盈率为16.92，低于行业平均值18.98[4] - MCK的PEG比率为1.56，与行业平均值1.80相近[5] - MCK的P/CF比率为18.67，低于行业平均值21.13[6] - 这些关键指标显示MCK目前可能被低估，结合其盈利前景，MCK看起来是一只令人印象深刻的价值股[7]

JHVEPhoto/iStock Editorial via Getty Images McKesson (NYSE:MCK) published their Q3 FY24 earnings on February 7th, reporting 15% topline growth and 12.2% adjusted EPS growth. I highlighted their growth opportunities in GLP-1 medications and their significant share buyback program in my introductory coverage. I maintain a 'Strong Buy' rating with a fair value of $660 per share. Strong GLP-1 Growth and Prior Authorization Network In Q3 FY24, McKesson delivered 15% revenue growth on a constant currency basis an ...